Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:ALEC NASDAQ:AMLX NASDAQ:ATHA NASDAQ:COYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$213.77+2.1%$209.49$180.25▼$244.81$369.98B0.326.62 million shs7.22 million shsALECAlector$2.11-0.5%$2.30$1.09▼$3.40$235.37M0.64550,061 shs790,427 shsAMLXAmylyx Pharmaceuticals$12.74-0.9%$15.24$4.64▼$18.60$1.43B-0.111.06 million shs1.13 million shsATHAAthira Pharma$10.13-10.0%$9.33$0.23▼$8.36$39.95M2.79602,475 shs24,355 shsCOYACoya Therapeutics$4.57-7.1%$4.38$3.71▼$7.75$115.41M0.55180,058 shs85,996 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.46%+3.34%+0.62%-9.93%+13.88%ALECAlector-1.85%+3.41%-17.51%+7.61%+73.77%AMLXAmylyx Pharmaceuticals-3.16%-13.58%-29.96%-8.99%+165.70%ATHAAthira Pharma0.00%+12.15%+27.09%+159.45%+313.97%COYACoya Therapeutics-0.81%+17.70%+2.93%+5.81%-17.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$213.77+2.1%$209.49$180.25▼$244.81$369.98B0.326.62 million shs7.22 million shsALECAlector$2.11-0.5%$2.30$1.09▼$3.40$235.37M0.64550,061 shs790,427 shsAMLXAmylyx Pharmaceuticals$12.74-0.9%$15.24$4.64▼$18.60$1.43B-0.111.06 million shs1.13 million shsATHAAthira Pharma$10.13-10.0%$9.33$0.23▼$8.36$39.95M2.79602,475 shs24,355 shsCOYACoya Therapeutics$4.57-7.1%$4.38$3.71▼$7.75$115.41M0.55180,058 shs85,996 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.46%+3.34%+0.62%-9.93%+13.88%ALECAlector-1.85%+3.41%-17.51%+7.61%+73.77%AMLXAmylyx Pharmaceuticals-3.16%-13.58%-29.96%-8.99%+165.70%ATHAAthira Pharma0.00%+12.15%+27.09%+159.45%+313.97%COYACoya Therapeutics-0.81%+17.70%+2.93%+5.81%-17.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.88Moderate Buy$253.4318.55% UpsideALECAlector 2.13Hold$3.6371.80% UpsideAMLXAmylyx Pharmaceuticals 2.77Moderate Buy$23.0080.53% UpsideATHAAthira Pharma 1.00Sell$4.00-60.51% DownsideCOYACoya Therapeutics 2.67Moderate Buy$16.00250.11% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, ALEC, ABBV, ATHA, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ABBVAbbVie EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$235.005/14/2026ABBVAbbVie Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$294.00 ➝ $298.005/8/2026AMLXAmylyx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.005/1/2026ABBVAbbVie GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$249.004/30/2026ABBVAbbVie DZ BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/30/2026ABBVAbbVie Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$262.00 ➝ $265.004/30/2026ABBVAbbVie Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$270.00 ➝ $278.004/30/2026ABBVAbbVie Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$240.004/30/2026ABBVAbbVie Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$234.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B6.18$15.47 per share13.82($3.74) per share-57.16ALECAlector$21.05M11.13N/AN/A$0.09 per share23.44AMLXAmylyx Pharmaceuticals$87.37M16.21N/AN/A$2.46 per share5.18ATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/ACOYACoya Therapeutics$7.95M13.49N/AN/A$2.09 per share2.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03105.3113.110.725.79%-576.45%13.39%7/30/2026 (Estimated)ALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)AMLXAmylyx Pharmaceuticals-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)ATHAAthira Pharma-$96.94M-$9.68N/AN/AN/AN/A-107.06%-89.89%N/ACOYACoya Therapeutics-$21.23M-$1.15N/AN/AN/A-266.10%-55.86%-48.86%N/ALatest AMLX, ALEC, ABBV, ATHA, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026COYACoya Therapeutics-$0.39-$0.32+$0.07-$0.32$0.15 million$0.25 million5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion3/16/2026Q4 2025COYACoya Therapeutics-$0.08-$0.34-$0.26-$0.34$1.93 million$3.96 million3/3/2026Q4 2025AMLXAmylyx Pharmaceuticals-$0.31-$0.30+$0.01-$0.30($0.05) millionN/A2/25/2026Q4 2025ALECAlector-$0.39-$0.34+$0.05-$0.34$1.78 million$6.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.923.24%+6.80%340.89%53 YearsALECAlectorN/AN/AN/AN/AN/AAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ALatest AMLX, ALEC, ABBV, ATHA, and COYA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/19/2026ABBVAbbViequarterly$1.733.32%4/15/20264/15/20265/15/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68ALECAlector0.805.255.25AMLXAmylyx PharmaceuticalsN/A17.8517.85ATHAAthira PharmaN/A9.709.70COYACoya TherapeuticsN/A15.0215.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ALECAlector85.83%AMLXAmylyx Pharmaceuticals95.84%ATHAAthira Pharma57.12%COYACoya Therapeutics39.75%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%ALECAlector8.30%AMLXAmylyx Pharmaceuticals12.30%ATHAAthira Pharma19.80%COYACoya Therapeutics12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableALECAlector270111.03 million101.81 millionOptionableAMLXAmylyx Pharmaceuticals200111.19 million97.51 millionOptionableATHAAthira Pharma403.94 million3.16 millionNo DataCOYACoya Therapeutics623.46 million20.64 millionNot OptionableAMLX, ALEC, ABBV, ATHA, and COYA HeadlinesRecent News About These CompaniesCoya 302 gets fast-track designation for ALS treatmentMay 18 at 5:11 PM | healio.comHDual-Action Biologic COYA 302 Receives FDA Fast Track Status for ALSMay 18 at 12:10 PM | neurologyadvisor.comNWall Street Zen Downgrades Coya Therapeutics (NASDAQ:COYA) to SellMay 16 at 1:31 AM | americanbankingnews.comCoya Therapeutics secures FDA fast track status for COYA 302May 14, 2026 | finance.yahoo.comFDA puts injection therapy COYA 302 on fast track for treating ALSMay 13, 2026 | alsnewstoday.comACoya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 13, 2026 | americanbankingnews.comCoya Therapeutics Inc COYAMay 12, 2026 | morningstar.comMCoya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)May 12, 2026 | pharmiweb.comPCoya Therapeutics Establishes $30 Million ATM Equity ProgramMay 12, 2026 | tipranks.comCoya Therapeutics Updates Q1 Results, COYA 302 ProgressMay 12, 2026 | tipranks.comCoya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 12, 2026 | businesswire.comCoya Therapeutics (COYA) Projected to Post Quarterly Earnings on TuesdayMay 10, 2026 | americanbankingnews.comCoya Therapeutics (COYA) Expected to Announce Earnings on TuesdayMay 5, 2026 | marketbeat.comCoya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in ...April 10, 2026 | finance.yahoo.comCoya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent DirectorApril 2, 2026 | pharmiweb.comPCoya Therapeutics Announces Leadership Changes and New DirectorApril 2, 2026 | tipranks.comCoya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy RatingMarch 23, 2026 | tipranks.comCoya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for ...March 18, 2026 | finance.yahoo.comCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial ResultsMarch 16, 2026 | pharmiweb.comPPlus Therapeutics (PSTV) Gets a Buy from Lake StreetMarch 6, 2026 | theglobeandmail.comCoya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?February 25, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026Berkshire Hathaway’s Record Cash Hoard: Why and What's Next?By Chris Markoch | May 5, 2026Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming DueBy Bridget Bennett | May 9, 2026Domino's Pizza: Outlook for the Berkshire Holding After Q1 DropBy Leo Miller | April 29, 20263 Crucial Aerospace Component Makers That Analysts LoveBy Nathan Reiff | May 16, 2026AMLX, ALEC, ABBV, ATHA, and COYA Company DescriptionsAbbVie NYSE:ABBV$213.77 +4.36 (+2.08%) Closing price 03:59 PM EasternExtended Trading$214.06 +0.28 (+0.13%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Alector NASDAQ:ALEC$2.11 -0.01 (-0.47%) Closing price 04:00 PM EasternExtended Trading$2.11 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Amylyx Pharmaceuticals NASDAQ:AMLX$12.74 -0.12 (-0.93%) Closing price 04:00 PM EasternExtended Trading$12.69 -0.05 (-0.39%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Athira Pharma NASDAQ:ATHA$10.13 -1.13 (-10.04%) As of 05/18/2026Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Coya Therapeutics NASDAQ:COYA$4.57 -0.35 (-7.11%) Closing price 04:00 PM EasternExtended Trading$4.56 -0.01 (-0.22%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
